Spark's Hemophilia B Gene Therapy SPK9001 Packs A Punch And Saves Big Bucks

A New England Journal of Medicine publication and editorial highlighted a small study of ten patients in which one infusion of Spark/Pfizer's SPK9001 gene therapy "nearly completely eliminated" the need for factor IX clotting products, saving $200,000 per patient per year.